DEF: Johnson & Johnson Faces Shareholder Scrutiny Over Executive Pay and Human Rights

Johnson & Johnson's upcoming annual meeting will address director elections, executive compensation, and shareholder proposals on severance packages and human rights impact assessments.

Summary

• This document is a proxy statement for Johnson & Johnson's 2025 Annual Meeting of Shareholders, scheduled for April 24, 2025.
• The meeting will be held in a virtual format.
• Shareholders will vote on several key items, including the election of 11 directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent accounting firm for 2025.
• Two shareholder proposals will also be presented: one requesting shareholder approval of excessive golden parachutes and another urging the production of a human rights impact assessment related to access to medicines.
• The Board of Directors recommends voting for the election of the director nominees and the ratification of the accounting firm, but against the two shareholder proposals.
• The document provides detailed information on corporate governance, director compensation, executive compensation, audit matters, and related party transactions.
• It also includes a discussion of the company's performance, risk management, and shareholder engagement activities.
• The proxy statement highlights Johnson & Johnson's commitment to its Credo, which emphasizes responsibilities to patients, employees, communities, and shareholders.
• Executive compensation is structured to align with performance, accountability, shareholder interests, and market competitiveness.
• The company's Enterprise Risk Management (ERM) framework and compliance programs are described, along with efforts related to cybersecurity, political spending, and environmental, social, and governance (ESG) matters.
• The document also details the company's stock ownership guidelines, compensation recoupment policies, and insider trading policy.

Sentiment

Score: 7

Explanation: The document presents a balanced view of Johnson & Johnson, highlighting both positive achievements and areas of concern. While the company demonstrates strong financial performance and commitment to its Credo, it faces challenges related to litigation, shareholder proposals, and achieving certain performance goals. The sentiment is cautiously optimistic, reflecting the company's overall strength but acknowledging existing headwinds.

Positives

• The company has a strong, independent Board leadership structure.
• The company has a proven record of strategic and consistent Board refreshment.
• The company has a comprehensive Code of Business Conduct and Ethics.
• The company has comprehensive compensation recoupment policies.
• The company has stock ownership guidelines for non-employee Directors and named executive officers.
• The company has a policy against pledging, hedging, and short selling of company stock.
• The company has a strong Lead Director with clearly defined duties and responsibilities.
• The company has active shareholder engagement throughout the year.
• The company has a new Executive Officer Cash Severance Policy that expressly requires shareholder approval for cash severance payments of the nature described in the proposal.
• The company has a longstanding and effective U.S. Severance Pay Plan that applies to all full-time U.S. employees who are involuntarily terminated and provides a maximum cash severance of 2.0x salary, well below the cash severance threshold of 2.99x the sum of salary and target bonus in the proposal.

Negatives

• The company's 2022-2024 Performance Share Units (PSUs) paid out at 63.6% of target, indicating underperformance against goals.
• The Board recommends voting against a shareholder proposal to produce a human rights impact assessment, which may be viewed negatively by some stakeholders.
• The company recorded an accounting charge of $5.1 billion related to talc matters in 2024.

Risks

• The company faces risks related to strategic, operational, financial reporting, compliance, environmental, social (e.g., human capital management) and cybersecurity issues.
• The company faces risks related to litigation, product quality and safety, cybersecurity, reputation, human capital and business performance.
• The company faces risks related to healthcare compliance, anti-corruption laws, and the manufacture and supply of products.
• The company faces risks related to supply chain, product quality, environmental regulations, employee health and safety, healthcare compliance, privacy, cybersecurity and political expenditures.
• The company faces risks related to the evolving, complex global environment in which the Company operates.

Future Outlook

The Board believes that Johnson & Johnson has a strong future and is committed to tackling the world's toughest health challenges.

Management Comments

• The Board continues to prioritize the collective skills and expertise that, taken together, promote effective guidance to the CEO and the Company’s Innovative Medicine and MedTech businesses.
• The Board also remains focused on the risks presented by the evolving, complex global environment in which the Company operates.
• Johnson & Johnson has proudly maintained a disciplined capital allocation strategy that affords it the opportunity to deploy capital across the enterprise in support of its patients, employees, shareholders and other stakeholders.

Industry Context

Johnson & Johnson operates in the healthcare industry, facing competition from other pharmaceutical and medical device companies. The company's performance is influenced by factors such as technological advances, new products, patent expirations, and regulatory changes.

Comparison to Industry Standards

• The document compares Johnson & Johnson's executive compensation practices to those of a peer group of companies, including 3M Company, Abbott Laboratories, AbbVie Inc., Amgen Inc., AT&T Inc., The Boeing Company, Bristol Myers Squibb Company, Cisco Systems, Inc., Eli Lilly and Company, General Electric Company, Gilead Sciences, Inc., Intel Corporation, International Business Machines Corp., Medtronic plc, Merck & Co., Inc., Microsoft Corporation, Pfizer Inc., The Procter & Gamble Company, and RTX Corporation.
• The document compares Johnson & Johnson's performance to the weighted performance of the competitor composite peer group companies.
• The document compares Johnson & Johnson's cumulative TSR with the peer indices.

Legal Proceedings

• The company recorded an accounting charge of $5.1 billion related to talc matters in 2024.
• Subsidiary Janssen sued to invalidate the Inflation Reduction Acts (IRAs) provision authorizing limited Medicare drug price negotiations.

Related Party Transactions

• A sister of Mr. Joseph Wolk, Executive Vice President, Chief Financial Officer, is a Mobility Operations Leader at Johnson & Johnson Services, Inc., a wholly-owned subsidiary of the Company, and earned $221,516 in total compensation in 2024.
• Ms. Kathryn Wengel is Executive Vice President, Chief Technical Operations & Risk Officer. Ms. Wengels brother-in-law is a partner at the law firm of Nelson Mullins Riley & Scarborough LLP (Nelson Mullins). In 2024, the Company paid approximately $17.97 million to Nelson Mullins for legal services.
• Certain of our U.S. and international employee savings and retirement plans and other affiliates have retained BlackRock and its affiliates to provide investment management services. In connection with these services, we paid BlackRock approximately $2 million in fees during fiscal year 2024.
• Certain of our U.S. and international employee savings and retirement plans and other affiliates have retained State Street and its affiliates to provide investment management, trustee, custodial, administrative and ancillary investment services. In connection with these services, we paid State Street approximately $8.9 million in fees during fiscal year 2024.

Stakeholder Impact

• The company's actions and decisions impact patients, doctors, nurses, employees, communities, and shareholders.
• The company is committed to providing high-quality products and services to patients.
• The company is responsible to its employees and strives to provide an inclusive work environment.
• The company is responsible to the communities in which it lives and works and supports good works and charities.
• The company is responsible to its stockholders and aims to make a sound profit and provide a fair return.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on April 24, 2025.
• The Board of Directors will continue to oversee the company's strategy, risk management, and compliance programs.
• The company will continue to engage with shareholders and address their concerns.

Key Dates